T. Rowe Price Investment Management
IONS icon

T. Rowe Price Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

T. Rowe Price Investment Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$462M Sell
6,159,027
-2,948,992
-32% -$233M 0.32% 82
2025
Q4 		$721M Sell
9,108,019
-4,048,910
-31% -$305M 0.45% 56
2025
Q3 		$861M Sell
13,156,929
-2,891,792
-18% -$141M 0.53% 46
2025
Q2 		$634M Sell
16,048,721
-126,812
-0.8% -$4.15M 0.4% 65
2025
Q1 		$488M Buy
16,175,533
+2,006,334
+14% +$65.7M 0.32% 89
2024
Q4 		$495M Buy
14,169,199
+1,083
+0% +$40.5K 0.31% 95
2024
Q3 		$568M Buy
14,168,116
+1,528,432
+12% +$71.1M 0.34% 84
2024
Q2 		$602M Sell
12,639,684
-677,428
-5% -$27.8M 0.38% 74
2024
Q1 		$577M Buy
13,317,112
+115,659
+0.9% +$5.51M 0.35% 78
2023
Q4 		$668M Buy
13,201,453
+78,398
+0.6% +$3.76M 0.43% 72
2023
Q3 		$595M Buy
13,123,055
+39,328
+0.3% +$1.62M 0.42% 68
2023
Q2 		$537M Buy
13,083,727
+19,680
+0.2% +$756K 0.37% 80
2023
Q1 		$467M Buy
13,064,047
+1,385,788
+12% +$52M 0.33% 85
2022
Q4 		$441M Buy
11,678,259
+521,564
+5% +$21.9M 0.34% 86
2022
Q3 		$493M Buy
+11,156,695
New +$470M 0.39% 72

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Investment Management's IONS Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Ionis Pharmaceuticals (IONS) stake by 32% in Q1 2026, selling an estimated $233M and leaving 6,159,027 shares worth $462M. The position accounts for 0.32% of the portfolio, ranked #82.

T. Rowe Price Investment Management first reported a position in IONS in Q3 2022 and has held it in 15 quarters since. The position peaked at $861M in Q3 2025. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • T. Rowe Price Investment Management held 6,159,027 shares of Ionis Pharmaceuticals worth $462M as of Q1 2026.
  • T. Rowe Price Investment Management sold 2,948,992 Ionis Pharmaceuticals shares in Q1 2026, an estimated $233M.
  • Ionis Pharmaceuticals made up 0.32% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #82 holding.
  • T. Rowe Price Investment Management first reported a position in Ionis Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • T. Rowe Price Investment Management's Ionis Pharmaceuticals position peaked at $861M in Q3 2025.
  • 494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.